Literature DB >> 8190434

Trial of labor following cesarean delivery.

R K Cowan1, R A Kinch, B Ellis, R Anderson.   

Abstract

OBJECTIVE: To examine several variables that may affect the success rate for a trial of labor after previous cesarean delivery, as well as those affecting the rate of uterine rupture.
METHODS: Between June 1, 1990 and December 31, 1991, we performed a consecutive, prospective study of 593 pregnant women who had had at least one abdominal delivery in the past, and attempted a trial of labor in each. Particular attention was given to the success rate of vaginal delivery, the type of previous uterine incision, use of oxytocin, estimated maternal blood loss, 5-minute Apgar scores, and reason for the previous cesarean operation.
RESULTS: Four hundred seventy-eight patients (81%) had a successful vaginal delivery. Oxytocin induction or augmentation was successful in 46 of 67 (69%) and 117 of 167 cases (70%), respectively. Estimated maternal blood loss was less than 500 mL in 453 cases (95%). Five patients (0.8%) experienced true uterine rupture, resulting in severe neurologic sequelae in one infant. The only consistent indication of uterine rupture was an abrupt and prolonged fetal bradycardia. The majority (463; 97%) of infants who were delivered vaginally had 5-minute Apgar scores of 8 or greater.
CONCLUSION: Our success rate of 81% suggests that a trial of labor after previous cesarean delivery is a safe and desirable option, but only after thorough patient counseling. An abrupt and persistent fetal bradycardia may be the only indication that uterine rupture has occurred.

Entities:  

Mesh:

Year:  1994        PMID: 8190434     DOI: 10.1097/00006250-199406000-00006

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  11 in total

1.  Rupture of a cesarean-scarred uterus: a community hospital experience.

Authors:  P A Poma
Journal:  J Natl Med Assoc       Date:  2000-06       Impact factor: 1.798

Review 2.  Systematic review of the incidence and consequences of uterine rupture in women with previous caesarean section.

Authors:  Jeanne-Marie Guise; Marian S McDonagh; Patricia Osterweil; Peggy Nygren; Benjamin K S Chan; Mark Helfand
Journal:  BMJ       Date:  2004-07-03

3.  The UTAH VBAC Study.

Authors:  Greg Gochnour; Stephen Ratcliffe; Mary Bishop Stone
Journal:  Matern Child Health J       Date:  2005-06

4.  A two-year review of uterine rupture in a regional hospital.

Authors:  Co Fofie; P Baffoe
Journal:  Ghana Med J       Date:  2010-09

5.  Delivery after prior cesarean: maternal morbidity and mortality.

Authors:  Yvonne W Cheng; Karen B Eden; Nicole Marshall; Leonardo Pereira; Aaron B Caughey; Jeanne-Marie Guise
Journal:  Clin Perinatol       Date:  2011-06       Impact factor: 3.430

6.  Trial of labor versus elective repeat cesarean section for the women with a previous cesarean section: a decision analysis.

Authors:  J H Chuang; R A Jenders
Journal:  Proc AMIA Symp       Date:  1999

7.  A Native American community with a 7% cesarean delivery rate: does case mix, ethnicity, or labor management explain the low rate?

Authors:  Lawrence Leeman; Rebecca Leeman
Journal:  Ann Fam Med       Date:  2003 May-Jun       Impact factor: 5.166

8.  Planned vaginal birth or elective repeat caesarean: patient preference restricted cohort with nested randomised trial.

Authors:  Caroline A Crowther; Jodie M Dodd; Janet E Hiller; Ross R Haslam; Jeffrey S Robinson
Journal:  PLoS Med       Date:  2012-03-13       Impact factor: 11.069

9.  "Endoview" project of intrapartum endoscopy.

Authors:  Boris M Petrikovsky; Steven Ravens
Journal:  JSLS       Date:  2002 Apr-Jun       Impact factor: 2.172

10.  Vaginal birth after caesarean versus elective repeat caesarean delivery after one previous caesarean section: a cost-effectiveness analysis in four European countries.

Authors:  Maaike Fobelets; Katrien Beeckman; Gilles Faron; Déirdre Daly; Cecily Begley; Koen Putman
Journal:  BMC Pregnancy Childbirth       Date:  2018-04-11       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.